e-ISSN: 2249 – 7781
Print ISSN: 2249 – 779X

International Journal of Pharmaceutical Research & Analysis
www.ijpra.com

Review Article

EVIDENCE-BASED MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE: PATHOPHYSIOLOGY, PHARMACOTHERAPY, AND THE EXPANDING ROLE OF PHARMACISTS

Shaik Suhani[1]*, Fathima Juwairia[1], Nagalakshmi M[1], Shaik Reshma[1], Dr Lavanya A[2]

[1]Pharm. D, IV Year Student, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India.
[2]Assistant Professor, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India.

ABSTRACT

Gastroesophageal reflux disease (GERD) is a common chronic gastroenterological ailment that is marked by the refluxing of gastric materials into the esophagus with resultant symptoms of heartburn, regurgitation as well as esophageal irritation. Chronic contact with acid may cause mucosal damage and lead to such complications as erosive esophagitis, Barrett esophagus, and risk of esophageal adenocarcinoma. Management of GERD needs to be evidence-based approach to the treatment incorporating pharmacological therapy, lifestyle change, and patient-centered care. The proton pump inhibitors are still the mainstay of treatment since they have strong acid-inhibitory effects, yet the histamine-2 receptor antagonists, antacids, and prokinetic agents serve as complementary treatment options. The correct dosing plans, deprescribing methods, and monitoring of the risks in the long-term are required to provide safe and effective treatment. Pharmacists and their role in the management of GERD is becoming increasingly relevant in terms of medication counseling, drug-drug interaction identification, lifestyle education, and early alertness of alarm symptoms that demand referral. Multidisciplinary and collaborative care has the potential to make therapeutic outcomes and patient quality of life much better.

Keywords: Gastroesophageal reflux disease; Proton pump inhibitors; Pharmacotherapy; Pharmacist interventions; Acid suppression.

INTRODUCTION

Gastroesophageal reflux disease (GERD) is among the most prevalent chronic gastrointestinal illnesses of the entire globe and a major clinical and public health issue. It arises as a result of refluxing of gastric contents especially of acid and pepsin into the esophagus, which happen as a result of lower esophageal sphincter dysfunction (LES), poor esophagic clearance or delayed gastric emptying [1–3]. The abnormal reflux causes irritation and inflammation of the esophageal mucosa, Which is as a consequence the cause of typical symptoms: heartburn, regurgitation, chest pain and dysphagia. GERD is a condition that occurs at any age and over the last several decades, its rates have grown significantly, mostly because of lifestyle and dietary shifts, the problem of obesity, and aging. Even though most patients do not develop ongoing and severe symptoms, chronic reflux may cause such complications as erosive esophagitis, esophageal strictures and Barrett esophagus and esophageal adenocarcinoma. The clinical features of GERD can be either typical (heartburn and acid regurgitation) or extra-esophageal (chronic cough, hoarseness, laryngitis, asthma exacerbations, and dental erosions), which can make diagnosis and treatment of the disease complicated. To effectively treat GERD it is necessary to adopt a multi-faceted approach to its treatment involving lifestyle change, pharmacological therapy and education of patients. Proton pump inhibitors (PPIs) are still a staple of pharmacological treatment as they have strong acid-suppressing effects, although

Corresponding Author
Shaik Suhani
Email :shaiksuhani8008@gmail.com

histamine-2 receptor antagonists, antibasic agents and prokinetic agents might be applied in certain clinical cases. During the past few years, more focus has been attracted on the optimization of dosing plans, reduction of the long-term adverse outcomes of acid-suppressive treatment, and the identification of the patients, who demand step-down or deprescribing plans. Healthcare providers with the pharmacist being a key stakeholder in managing GERD by providing engagement in counseling patients about medication adherence, monitoring drug-drug interactions, and providing lifestyle adaptations that minimize recurrence of symptoms. The multidisciplinary and patient-centered approach would thus play a significant role in enhancing the therapeutic effects, complication avoidance, and overall quality of life of people with GERD [5].

Pathophysiology of GERD

Gastroesophageal reflux disease (GERD) arises when various physiological changes happen that interfere with the normal protective processes that ensure that the gastric contents do not move to the esophagus. In the absence of complications, the lower esophageal sphincter (LES) is functional, and it helps to maintain a high-pressure zone between the esophagus and the stomach to avoid the reflux of acidic gastric contents. The barrier activity is compromised in GERD by transient low esophageal sphincter relaxations (TLESRs), lower LES pressure or structural pathology (hiatal hernia) [6, 7]. TLESRs are believed to be the main mechanism that causes reflux episodes because it enables the passage of gastric contents to the esophagus without necessarily having to swallow. Besides the malfunctioning of the sphincter, poor esophageal clearance is also found to be an important cause of the GERD pathogenesis. In GERD patients, the refluxed acid mainly remains in contact with the esophageal mucosa longer than it does in normal, because of poor peristaltic contractions and inadequate salivary buffering, the probability of mucosal injury also rises. Slow gastric emptying is also a causative factor of GERD because it raises the volume and pressure of the gastric contents that encourages refluxes. Another factor of importance in the development of diseases is the composition of reflux ate. In addition to hydrochloric acid, pepsin, bile acids, and pancreatic enzymes may be found in refluxed material and cause damage to the esophageal epithelium and lead to inflammation. The recurring exposure of the esophageal mucosa to these damaging ingredients causes distortion of epithelial tight junctions, mucosal permeability and induction of cytokine and immune-mediated inflammatory pathways. In the long run, the erosive esophagitis, ulceration and remodeling of the esophageal epithelium may be the outcome of this chronic inflammatory process. In other patients, chronic damage causes intestinal metaplasia of the form of Barretts esophagus, which carries with it a high risk of esophageal adenocarcinoma. Moreover, the severity of the symptoms may also be due to visceral hypersensitivity and perception of pain distortion despite the lack of considerable mucosal damage. Therefore, GERD is a multifactorial disease that comprises of the malfunction of the anti-reflux barrier, esophageal clearance, delayed stomach empties, and inflammatory injury of the mucosa. These complicated processes should be understood to formulate effective therapeutic approaches and enhance the management of the disease in the long term [8, 9].

Acid Exposure and Mucosal Injury

Overexposure of the esophageal mucosa to acid is a focal cause of the pathogenesis and progression of the gastroesophageal reflux disease (GERD). In the normal physiological situation, there are a number of defense mechanisms in esophageal epithelium that include the lower esophageal sphincter defense, esophageal peristalsis defense, mucosal secretion of bicarbonate and the protective mucus lining that prevents the direct contact of gastric contents and the epithelial cells[4,7,10]. Nonetheless, the impairment of these defensive factors results in the case of recurrent reflux of acidic gastric contents to the esophagus, which causes extended acid exposure and following mucosal damage. Hydrochloric acid and pepsin are usually present in gastric refluxate and they are both important factors that harm the lining of the esophagus. Acid interferes with the integrity of epithelial tight junctions which enhances mucosal permeability and admits hydrogen ions into the mucosa deeper. This intrusion causes cell damage, inflammation and the stimulation of the sensory nerve endings, which help in the symptomatic heartburn and chest pain. Pepsin also causes more damage to the injury by damaging epithelial proteins and disabling the mucosal defense mechanisms. Bile acids and pancreatic enzymes that are found in duodenogastric reflux may contribute to mucosal damage and be exacerbating in patients with severe or chronic reflux. Repeated exposure to these violent factors triggers an inflammatory cascade with the release of cytokines, chemokines and reactive oxygen species recruiting immune cells and increasing tissue damage. Histologically, the process can be represented by the erosion of epithelium, the hyperplasia of the basal cells, elongement of the papillae, and inflammatory cell infiltration in the esophageal mucosa. With prolonged acid exposure, recurrent phases of injury and repair could result in the development of complications including erosive esophagitis, the development of ulcers, and fibrotic strictures. Chronic mucosal injury in a few people triggers adaptive modification in the epithelium, leading to intestinal metaplasia (so-called Barretts esophagus) a premalignant condition with a risk of developing esophageal adenocarcinoma. Thus, the acuteity and length of acid

exposure are vital factors that influence the damage of the mucosa and clinical outcomes of GERD. It is important to understand the mechanisms that cause acid induced mucosal injury in order to help in informing effective therapeutic approaches to help reduce acid secretion, increase mucosal protection and avoid disease progression [11,12].

Pharmacotherapy of GERD

Pharmacotherapy is at the center stage of treating the gastroesophageal reflux disease (GERD) and is mainly designed to lower the amount of acid secreted in the stomach, alleviate the symptoms, facilitate the healing of the mucosa, and prevent the complications of chronic reflux. Pharmacological therapy prescribed is based on the severity of symptoms, whether or not the patient suffers esophageal mucosal damage, and the response to treatment [14]. The proton pump inhibitors (PPIs) have been reported as the first-line treatment of the GERD because they are better in suppressing secretion of gastric acid, which is caused by irreversible inhibition of the hydrogen, potassium ATPase enzyme system within the gastric parietal cells. PPIs like omeprazole, pantoprazole, esomeprazole, rabeprazole and lansoprazole are effective in the management of the symptoms and healing of erosive esophagitis because they reduce the production of gastric acid substantially. The agents are usually given once a day before meals but twice a day dosages could be necessary in patients with severe or refractory symptoms. Another group of acid-suppressive agents, which decreases the secretion of gastric acid by blocking the histamine receptors on gastric parietal cells, is termed histamine-2 receptor antagonists (H2RA) and includes ranitidine, famotidine, cimetidine, and nizatidine. Although H2RAs can be useful to treat mild to moderate symptoms of GERD, they are not as strong as PPIs and can be linked to the occurrence of tachyphylaxis over the long-term period. Antacids are generally used as a quick symptomatic approach by counteracting the current level of gastric acid to help in short-term treatment of heartburn and dyspepsia. All of which are usually made up of aluminum hydroxide, magnesium hydroxide, calcium carbonate or sodium bicarbonate, they are often used as over-the-counter drugs to relieve intermittent symptoms. In some instances, prokinetic medications like metoclopramide or domperidone can be used to promote gastric emptying and to increase esophageal motility and minimize the number of refluxes. Furthermore, the formulations based on alginate could be applied to create a protective layer that could not allow the reflux of the gastric fluid into the esophagus. Pharmacological management of GERD is usually coupled with lifestyle changes which include weight loss, change in diets and avoidance of triggers of reflux symptoms. The correct choice of therapy, personalized dosing plans, and attentive observation of long-term therapy are necessary to ensure the best symptom management, low adverse effects, and increase the overall life quality of GERD patients.[12].

Dosing Strategies (On-Demand vs Maintenance)

The pharmacological management of gastroesophageal reflux disease (GERD) dosing strategies are aimed at giving efficient symptom control and decrease unnecessary long-term drug exposure [15]. Two of the most common therapeutic interventions are on-demand therapy and maintenance therapy and both of these are chosen depending on the severity of symptoms, complications presence and reaction of patient to initial treatment. The on-demand therapy involves intermittent use of medicine which most often is the proton pump inhibitor (PPI) and histamine 2 receptor antagonist (H2RA) and this type of medication is administered only in instances where the symptoms occur and withdrawn once the symptoms are reduced. The strategy is mainly applicable to patients with non-erosive reflux disease (NERD) or with mild and rare symptoms. Demand dosing aids in reducing the intake of the medication in general, decreasing medication expenses, and reducing the chance of the potential adverse effects of a long-term acid inhibition. The patients are normally advised to use the medicine on the appearance of the symptoms or even on a short term use when the symptoms re-occur. Conversely, maintenance therapy refers to continuous and consistent use of acid-suppressive drugs to avoid the reoccurrence of the symptoms and allow eventual healing of the esophageal mucosa. The patients with severe GERD, erosive esophagitis, Barretts esophagus, or recurring relapse of symptoms following withdrawal of treatment should be provided with maintenance therapy. The number one most used agent in the maintenance therapy is the proton pump inhibitors due to their high and prolonged acid suppression. A step-down method is used in most instances whereby patients are initially given standard or high dose PPI therapy to ensure symptom control and mucosal healing and then gradually reduced to the minimal effective dose or switched to on-demand therapy. Intermittent therapy (whereby patients take medication in pre-established short-course treatment of symptoms) may be useful to some patients as well. It is necessary to individualize dosing plans depending on the patient features, severity of the disease, and his or her response to the therapy to maximize treatment effects. Pharmacists in particular have a crucial role to play in patient education on proper dosing patterns, adherence, and proper and safe use of GERD medications to effectively control symptoms, and reduce the risk of harm in the long term [15,16].

Duration of Therapy and Deprescribing

Pharmacological treatment of gastroesophageal reflux disease (GERD) is a condition in which the length

of the treatment depends on the severity of the symptoms, the existence of an esophageal mucosal injury, and the response of the patient to medication. Mostly proton pump inhibitors (PPIs) are prescribed as first-line treatment and are usually started as a short-course treatment of between 4-8 weeks to induce symptom relief and esophagitis healing [17]. In most cases, this first line of treatment is adequate to patients with mild to moderate GERD or non-erosive reflux disease. Once the patient has been controlled, clinicians ought to re-evaluate the patient to see whether the patient needs to be continued with therapy or whether the drug dose can be given at a lower dose. Symptoms of GERD, in most cases, can recur after the therapy is stopped and the problem is not necessarily to be treated on a permanent basis. Thus, step-down therapy, intermittent therapy, or use of acid-suppressive drugs on demand are frequently prescribed to reduce the number of hours of exposure to any drug and still achieve a sufficient level of control of the symptoms. The idea of deprescribing has gained a significant role in the management of GERD especially given the fears about the possible adverse effects of long-term use of PPI. Deprescribing is the deliberate attempt to decrease the dose, administer a weaker agent, or drop medication in case the clinical advantages no longer surpass the potential risks. Deprescribing is suitable to patients who had initially needed PPIs to control their simple GERD and who have obtained stable symptoms control. This can be done by slowly reducing the dose of PPI to avoid rebound secretion of acid which is succeeded by the use of histamine-2 receptor antagonists or antacids in case of need. During deprescribing, lifestyle changes, such as eating habits, weight loss, and the avoidance of reflux-inducing habits, ought to be highlighted to contribute to the maintenance of the symptoms. Nevertheless, patients with complications, including severe erosive esophagitis, Barrett esophagus, or persistent recurrence of symptoms may still need long-term or indefinite treatment. A meticulous assessment of patients, tailored treatment planning and continual follow-up are needed to make sure that the methods of deprescribing are applied safely without jeopardizing effective GERD symptoms regulation and preventing the reoccurrence of the disease [18–21]

Table 1: Pharmacological Agents Used in the Management of Gastroesophageal Reflux Disease

Drug Class	Mechanism of Action	Common Drugs	Clinical Role in GERD
Proton Pump Inhibitors (PPIs)	Irreversibly inhibit H^+/K^+-ATPase in gastric parietal cells, suppressing acid secretion	Omeprazole, Pantoprazole, Esomeprazole, Rabeprazole, Lansoprazole	First-line therapy for moderate to severe GERD and erosive esophagitis
Histamine-2 Receptor Antagonists (H2RAs)	Block histamine H2 receptors in gastric parietal cells, reducing acid secretion	Famotidine, Nizatidine, Cimetidine	Mild to moderate GERD, nocturnal acid suppression
Antacids	Neutralize gastric acid in the stomach	Aluminum hydroxide, Magnesium hydroxide, Calcium carbonate	Rapid symptomatic relief for intermittent heartburn
Prokinetic Agents	Enhance gastric emptying and increase esophageal motility	Metoclopramide, Domperidone	Adjunct therapy in patients with delayed gastric emptying
Alginate Preparations	Form a protective gel barrier that prevents reflux of gastric contents	Sodium alginate combinations	Symptomatic relief and prevention of reflux episodes

Table 2: Dosing Strategies in the Pharmacological Management of GERD

Treatment Strategy	Description	Suitable Patients	Clinical Advantages
On-Demand Therapy	Medication taken only when symptoms occur and stopped after relief	Patients with mild GERD or non-erosive reflux disease (NERD)	Reduces drug exposure, cost-effective
Maintenance Therapy	Continuous daily medication to prevent symptom recurrence	Patients with erosive esophagitis or severe GERD	Maintains mucosal healing and prevents relapse
Step-Down Therapy	Gradual reduction from higher-dose therapy to lowest effective dose	Patients responding well to initial therapy	Minimizes long-term drug exposure
Intermittent Therapy	Short treatment courses when symptoms recur	Patients with periodic GERD symptoms	Provides symptom control without continuous medication



Figure:1 Duration of Therapy and Deprescribing

Drug–Drug Interactions

The pharmacological treatment of gastroesophageal reflux disease (GERD) should not exclude drug-drug interactions, since acid-suppressive drugs like proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) often have an extended treatment duration and are commonly administered alongside with other drugs. The proton pump inhibitors such as omeprazole, esomeprazole, pantoprazole and lansoprazole are mostly metabolized by the cytochrome P450 (CYP450) enzyme system of the liver especially by CYP2C19 and CYP3A4 enzymes. Consequently, they can affect the metabolism of other drugs which depend on the same enzymatic pathways. Indicatively, omeprazole and esomeprazole are able to inhibit CYP2C19, which can weaken the activation of some prodrugs like clopidogrel thereby reducing its antiplatelet effects and endangering the development of cardiovascular events in most sensitive patients [22–24]. Also, PPIs can react with medications, the absorption of which depends on the gastric pH. As these drugs greatly lower gastric acidity, they may impair the absorption of drugs that need an acidic pH to be absorbed optimally, such as ketoconazole,itraconazole, atazanavir and some iron salts. On the other hand, absorption of certain drugs may elevate under conditions that are less acidic. The possibility of drug interactions with histamine-2 receptor antagonists also exists, but not the extent of PPIs in most cases. One drug specifically cimetidine has been known to inhibit various CYP450 enzymes and even raise plasma levels of other drugs, including warfarin, phenytoin, theophylline, and some benzodiazepines, potentially resulting in either exaggerated pharmacological action or increased toxicity. Other H2RAs like famotidine and nizatidine on the other hand have fewer clinically significant interactions. Antacids can also influence drug absorption with co-administered drugs by lowering or increasing the occurrence of insolubility of other drugs (i.e., tetracycline antibiotics, fluoroquinolones, levothyroxine, etc.), as well as by changing the gastric pH. Hence, correct dosing interval spacing is usually recommended in cases where antacids are taken together with such agents. The medication history of a patient should be carefully analyzed to determine possible interactions, structure the therapeutic effect, and reduce the adverse effect. The pharmacists are healthcare professionals who are important in identifying drug-drug interactions, medication counseling, and effective and safe pharmacotherapy of patients with GERD [25].

Pharmacist-Led Interventions

Pharmacist-initiated interventions are crucial to the overall management of gastroesophageal reflux disease (GERD) because they enhance medication adherence, improve patient adherence, and secure the safe and effective treatment. Pharmacists have a good chance to assess patients at the earliest stage, prescribe suitable over-the-counter drugs, and refer patients to evidence-based treatment options because they have a large amount of contact with patients and are likely to notice any symptoms [25–27]. Medication counseling is one of the most essential roles of pharmacists, and it involves the training of patients on the right use of acid-

suppressive medications including proton pump and histamine-2 receptor antagonists (H2RAs), antacids. As an illustration, pharmacists can educate the patients to take PPIs 30-60 minutes before meals as this will help the medications be the most effective, clarify when the patients should expect to feel better, and to show the patients that their medications have to be taken as prescribed. Pharmacists are also involved in establishing possible drug-drug interactions, the history of medications, and that the GERD medications do not interact with any other treatment that the patient is undergoing. Besides medication management, pharmacists also help with education and lifestyle counseling of patients, instructing them on dietary change, weight loss, smoking cessation, and avoiding reflux triggering foods like fatty food, caffeine, alcohol and spicy food. Such interventions are capable of greatly minimizing the recurrence of symptoms and enhancing the outcomes in the long run. Pharmacists can also play a significant role in the support of deprescribing plans, especially in patients who have been taking proton pump inhibitors over a long period without any evident hints. Pharmacists can assist in identifying patients that could be placed on step-down therapy, reduce their dosages, or change to on-demand treatment through medication review and communication with physicians. Moreover, the pharmacists are able to track the response of the treatment, determine the persistence of the symptoms and identify the symptoms of alarm, which are dysphagia, unexplainable weight loss, gastrointestinal bleeding, or chronic vomiting that can lead to referral to the physician and further examination. Through medication management, patient counseling, monitoring, and interprofessional collaboration, pharmacist-led interventions will play an important role in optimizing GERD therapy, medication-related risk minimization, and overall quality of care of patients with this prevalent gastrointestinal disorder [16].

Lifestyle Modification Counseling

Lifestyle modification counseling is necessary part of the treatment of gastroesophageal reflux disease (GERD) which is usually advised along with the pharmacological treatment to minimize the degree of symptoms and avoid their recurrence. Pharmacists and other medical practitioners are significant in informing patients on lifestyle habits which have the potential to affect the reflux episodes and esophageal irritation. Weight management is one of the most effective interventions because being overweight raises the intra-abdominal pressure and facilitates refluxing of the gastric contents into the esophagus [26]. Promoting healthy body weight by balancing what is consumed and engaging in physical exercise would greatly enhance the symptoms of GERD. They should also include dietary changes because some food and drinks provoke reflux or lower the esophageal sphincter. Reflux patients are usually advised to reduce or avoid fatty and fried, chocolate, caffeine, carbonated drinks, hot foods, citrus fruits, and alcohol which can worsen the symptoms of reflux in prone sufferers. The other important suggestion is not to eat in large volumes and at late hours, as large amounts of food elevate gastric pressure and predispose towards reflux. Patients are suggested to consume smaller meals more frequently and not go to bed within two to three hours after they eat. Another way of preventing nighttime reflux is by raising the head of the bed about 15-20 centimeters when sleeping and this is because the use of gravity helps in ensuring that the contents in the stomach do not move up to the esophagus. The cessation of smoking is highly recommended because nicotine may decrease the lower esophageal sphincter pressure and inhibit the esophageal clearance. Also, patients are to be advised against tight-fitting clothes near the abdomen as these could raise the pressure on the abdominal cavity and enhance the symptoms of reflux. Some people can also be successfully treated by stress management techniques, such as relaxation exercises and getting enough sleep. By delivering good advice regarding such lifestyle practices, medical experts can empower patients to engage in self-care in the management of their diseases, increase the efficacy of pharmacological treatment, and decrease the incidence and intensity of GERD symptoms and improve the overall gastrointestinal wellness and quality of life [20].

Referral Criteria for Alarm Symptoms

Referral criteria of the alarm symptoms is a critical element in the management of gastroesophageal reflux disease (GERD) due to the fact that some of its clinical manifestations can denote existence of underlying serious conditions that need timely medical attention. Although the cases of GERD could be successfully treated by the use of lifestyle changes and pharmacological treatment, the presence of particular warning symptoms, also known as alarm symptoms, predetermines the need to address a physician or a gastroenterologist to be diagnosed further. Among the most important alarm symptoms are the dysphagia or difficulty in swallowing, that can be an indication of esophaginal compression, stricture, or a possible malignancy. Equally, painful swallowing, known as odynophagia, may be a sign of inflammation or ulceration of the esophagus of a severe nature. Another severe symptom that is to be investigated urgently is unintentional weight loss because it could be linked to chronic illness, malignancy, and severe gastrointestinal pathology. Patients that present with gastrointestinal bleeding, which can be described as hematemesis (vomiting blood) or melena (black, tarry stools) or unexplainable anemia should also be urgently referred to be evaluated as this symptom can be associated with

esophaginal ulceration, severe esophagitis or other severe gastrointestinal diseases. Continuous vomiting, in particular, with dehydration or electrolyte imbalance will also be a reason to refer and conduct additional clinical research. Also, patients with symptoms of refractory GERD, that is, those that do not respond to proper pharmacological treatment, especially following a sufficient course of proton pump inhibitors should undergo additional diagnostic tests, including endoscopy or esophageal pH analysis. The alarm symptoms that appear in the patients who develop new-onset reflux symptoms at the age of 50 and above also need a special consideration because they are at a higher risk of developing complications. Such precautionary pointers must be recognized at the earliest and proper referral made to avoid further development of the disease and the development of possible complications like Barretts esophagus or esophagial cancer. Pharmacists and other medical workers are significant in identifying these symptoms when interacting with patients and refer them to timely medical care. Healthcare providers can contribute to patient safety and clinical outcomes by making sure that patients with alarm symptoms undergo proper specialist assessment in the treatment of GERD [28,29].

Monitoring Safety and Long-Term Risks

Safety and long-term risks should be monitored as a part of the gastroesophageal reflux disease (GERD) management, especially in patients who are on pharmacological therapy with acid-suppressive medications, including proton pump inhibitors (PPIs) and histamine- 2 receptor antagonists(H2RAs) on a long-term basis. Though these drugs are very suitable in managing the acid secretion of the stomach and alleviating the symptoms of GERD, there are a number of possible side effects associated with the long term use of these drugs which should be closely monitored. Persistent acid blockage may modify the physiological conditions of the gastrointestinal tract and affect the absorption of the nutrients, the microbial flora, and macro-metabolism. Among the most important safety issues related to the long-term PPI treatment is a possibility of developing nutrient deficits, such as the diminished intake of vitamin B12, magnesium, calcium, and iron. Reduced gastric acidity has the potential to reduce the release and absorption of these nutrients, potentially leading to anemia, neuromuscular disorders or metabolic defects in vulnerable individuals. Bone-related complications have also been associated with long-term PPI therapy, especially predisposition to osteoporosis related fractures because of decreased calcium absorption rate and potentially by acting upon bone metabolism. Also, chronic acid suppression can predispose to some infections, gastric acid is a protective lining in the stomach against the pathogens that are ingested. Patients undergoing long-term treatment thus are at increased risk of developing gastrointestinal infections like Clostridios difficile infection and other enteric organisms. Additionally, a few of the observational studies have also indicated potential causal relationships between chronic kidney disease, gastric polyps or imbalances of certain micronutrients and long-term PPI use, but the causal effect in most instances is still under study. Consistency We should therefore recommend that patients undergoing extended acid-suppressive therapy should be reviewed on a regular basis to ensure that they are only given the minimal effective dose and that the treatment is still clinically reasonable. The clinicians are also supposed to review the necessity of continuing the therapy periodically, review the symptoms control, the adverse effects, and deprescribing strategies should be considered in the case of an adequate need. Pharmacists have a very significant role in the area of medication review, patient counseling and determining the possible safety issues associated with long-term treatment. By adopting a close follow-up and personalized treatment planning, healthcare professionals will be able to maximize the GERD treatment process and reduce the associated risks of long-term pharmacological treatment [23,26].

Bone Health and Fracture Risk

The bone condition and the risk of a fracture has become a fundamental thought in patients under long-term pharmacological treatment of gastroesophageal reflux disease (GERD), especially when taking proton pump inhibitors (PPIs) [30–33]. The reason why PPIs are extensively prescribed is their high potential in reducing the secretion of gastric acid and increasing the healing of esophageal mucosal damage but long-term acid suppression can affect the mineral density of bones and calcium metabolism. The gastric acid is significant in solubilization and absorption of dietary calcium particularly calcium carbonate. In the face of extensive PPI treatment when gastric acidity is greatly lowered, calcium absorption can be inhibited, and in the long run, bone mineralization can be depressed. This potential outcome can lead to a decrease in bone strength and an increased risk of fracture especially in those who are considered at risk due to age like the elderly patients, females who are postmenopausal or those patients who already have osteoporosis or other metabolic bone diseases. Various epidemiological research studies have argued that there is a correlation between long term PPI usage with a higher risk of osteoporotic fractures, especially hip, wrist and spine. The possible causes, even though their mechanisms are still under research, may be impaired calcium absorption, secondary hyperparathyroidism, and bone remodelling changes associated with osteoclasts. Also, there are chances that chronic PPI treatment causes magnesium deficiency that indirectly impacts the bone metabolism and weakens

skeletal health. The risk is likely to be more significant among patients who are on a high dose or prolonged PPI therapy, after one year of continuous therapy. In order to reduce these risks, medical workers must critically consider the need of long-term acid-suppressive therapy and strive to achieve the lowest effective dose within the shortest possible duration of time to manage the symptoms of GERD [23,34–36]. When patients are at high risk of osteoporosis, nutrient that includes calcium and vitamin D should be taken in proper and adequate amounts either by consuming it with food or by taking it in adequate amounts as supplementation. Another crucial activity that helps in sustaining bone health is weight-bearing exercise, quitting smoking, and alcohol moderation. Long-term monitoring of bone mineral density may also be involved in the management of the high-risk individuals. Pharmaceutical workers and other healthcare professionals are also significant in advising patients of these dangers to review the medication regimen and to make sure that preventive measures are taken to preserve bone health without jeopardizing the treatment of GERD [37–41].

CONCLUSION

Gastroesophageal reflux disease (GERD) has been among the most common gastrointestinal diseases across the world and has remained to be a major clinical and global health problem. It pathophysiology is complex interactions between dysfunction of lower esophageal sphincter, esophageal clearance impairment, delayed gastric emptying and ambient exposure to acid which causes mucosal injury and symptomatic disease. Treatment of GERD needs to incorporate the evidence based and patient centered approach that combines pharmacological treatment, lifestyle changes and ongoing clinical observation. Proton pump inhibitors continue to be the pillar in treatment because they have a high acid-suppressive effect and have been shown to be effective in the treatment of symptoms and mucosal healing. Nevertheless, the necessary dosing plan, on-demand therapy, maintenance therapy, and deprescribing methods are vital factors to reduce the needless long-term drug consumption and risks. It is also important to monitor possible adverse effects of nutrient deficiency, bone issues, and the risk of infection in patients under long-term care on acid-suppressive therapy. Pharmacists are becoming very significant in the process of maximizing the management of GERD by counseling on the use of drugs, detecting drug-drug interactions, educating patients on lifestyle, and early detection of red flag symptoms that necessitate medical attention. It is thus necessary to have a multidisciplinary approach that involves physicians, pharmacists, and patients so that there could be safe, effective, and sustainable management of GERD and better long-term clinical outcomes and quality of life of patients.

REFERENCES

1. Bucan JI, Braut T, Krsek A, Sotosek V, Baticic L. *et al.* Updates in gastroesophageal reflux disease management: from proton pump inhibitors to dietary and lifestyle modifications. *Gastrointest. Disord*.7(2), 2025, 33.
2. Hossa K, Małecka-Wojciesko E. Advances in gastroesophageal reflux disease management: exploring the role of potassium-competitive acid blockers and novel therapies. *Pharmaceuticals,* 18(5), 2025, 699.
3. Ahmed S, Asghar S, Khanzada M, Soxi F, Gundala Raja H, Gul M, *et al.* Comparing proton pump inhibitors and emerging acid-suppressive therapies in gastroesophageal reflux disease: a systematic review. *Cureus,* 17, 2025, e84311.
4. Tanvir F, Nijjar GS, Aulakh SK, Kaur Y, Singh S, Singh K, *et al.* Gastroesophageal reflux disease: new insights and treatment approaches. *Cureus*, 16, 2024, e67654.
5. Kim SY, Lee KJ. Potential risks associated with long-term use of proton pump inhibitors and the maintenance treatment modality for patients with mild gastroesophageal reflux disease. *J. Neurogastroenterol. Motil*., 30(3), 2024, 407–420.
6. Zheng Z, Shang Y, Wang N, Liu X, Xin C, Yan X, *et al*. Current advancement on the dynamic mechanism of gastroesophageal reflux disease. *Int. J. Biol. Sci.,* 17(15), 2021, 4154–4164.
7. Sintusek P, Mutalib M, Thapar N. *et al* Gastroesophageal reflux disease in children: what's new right now? World J. *Gastrointest. Endosc., 15(3), 2023, 84–102.*
8. Komolafe K, Komolafe TR, Crown OO, Ajiboye B, Noubissi F, Ogungbe IV, *et al* Natural products in the management of gastroesophageal reflux disease: mechanisms, efficacy, and future directions. Nutrients, 17(6), 2025, 1069.
9. Bertin L, Savarino V, Marabotto E, Ghisa M, De Bortoli N, Savarino EV. *et al* Pathophysiology of gastroesophageal reflux disease. *Digestion,* 2025,
10. Yang W, Huang Y, He L, Chen D, Wu S, Tian Y, *et al* Utilizing esophageal motility tests in diagnosing and evaluating gastroesophageal reflux disease. *Diagnostics,* 14(14), 2024, 1467.
11. Visaggi P, Bertin L, Pasta A, Calabrese F, Ghisa M, Marabotto E, *et al*. Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024. *Expert Opin. Pharmacother*., 25(18), 2024, 2077–2088.
12. Raza D, Mohiuddin F, Khan MH, Fawad M, Raza SM. *et al* Childhood gastroesophageal reflux disease: a comprehensive review of disease, diagnosis, and therapeutic management. *World J. Clin. Pediatr*.14(2), 2025, 101175.
13. Zhu X, Shen J. Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease. *Eur. J. Med. Res.,* 29, 2024, 1789.

14. Ramani A, Merchant A, Cash BD. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease. *Eur. J. Clin. Pharmacol.,* 79(7), 2023, 1023–1029.
15. Kang SH, Moon HS, Sung JK, Kim SM, Kim KB, Lee SW, *et al.* Assessment of the efficacy of on-demand tegoprazan therapy in gastroesophageal reflux disease through a randomized controlled trial. Sci. Rep., 15, 2025, 84065.
16. Umeh AU, Chima UE, Agbo CE, Chiekwe OS, Eze AE, Nwachuya CA, *et al.* Pharmacist-led medication therapy management: impact on healthcare utilization and costs. *AJPPS,* 4(1), 2025, 4.
17. Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. *World J. Gastroenterol.,* 28(28), 2022, 3608–3619.
18. Jung H-K, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, *et al* 2020 Seoul consensus on the diagnosis and management of gastroesophageal reflux disease. *J. Neurogastroenterol. Motil.,* 27(4), 2021, 453–481.
19. Kang SJ, Jung H-K, Tae CH, Kim SY, Lee KJ. *et al* On-demand versus continuous maintenance treatment of gastroesophageal reflux disease with proton pump inhibitors: a systematic review and meta-analysis. *J. Neurogastroenterol. Motil.,* 28(1), 2022, 5–14.
20. Davis TA, Gyawali CP. Refractory gastroesophageal reflux disease: diagnosis and management. *J. Neurogastroenterol. Motil.,* 30(1), 2024, 17–28.
21. Ivashkin VT, Trukhmanov AS, Maev IV, Drapkina OM, Livzan MA, Martynov AI, *et al* Diagnosis and treatment of gastroesophageal reflux disease (clinical guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Community for Human Microbiome Research). Ross. Z. Gastroenterol. *Gepatol*. Koloproktol.,34(5), 2024, 111–135.
22. Scott DR, Munson KB, Marcus EA, Lambrecht NWG, Sachs G. *et al* The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. *Aliment. Pharmacol. Ther.,* 42(11-12), 2015, 1315–1326.
23. Andrawes M, Andrawes W, Das A, Siau K. *et al* Proton pump inhibitors (PPIs)—an evidence-based review of indications, efficacy, harms, and deprescribing. *Medicina,* 61(9), 2025, 1569.
24. Marker T, Steimbach RR, Perez-Borrajero C, Luzarowski M, Hartmann E, Schleich S, *et al*. Site-specific activation of the proton pump inhibitor rabeprazole by tetrathiolate zinc centres. *Nat. Chem.,* 17(4), 2025, 507–517.
25. Ernawati I, Munif Yasin N, Setyopranoto I, Ikawati Z. *et al* The role of pharmacists' interventions in increasing medication adherence of patients with epilepsy: a scoping review. *J. Prev. Med. Public Health*, 57(4), 2024, 212–222.
26. Herdiana Y. Functional food in relation to gastroesophageal reflux disease (GERD). *Nutrients,* 15(16), 2023, 3583.
27. Farhana L, Rahayu F, Sholihah S, Sweileh W, Abdulah R, Alfian S. *et al* Effectiveness of pharmacist-led intervention on medication adherence in chronic diseases: a systematic review of randomized controlled trials. *Patient Prefer. Adherence,* 19, 2025, 2161–2178.
28. Herregods TVK, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJPM. *et al* Patients with refractory reflux symptoms often do not have GERD. *Neurogastroenterol. Motil.,* 27(9), 2015, 1267–1273.
29. Kroch DA, Madanick RD. Medical treatment of gastroesophageal reflux disease. *World J. Surg.,* 41(7), 2017, 1678–1684.
30. Thong BKS, Ima-Nirwana S, Chin K-Y. *et al* Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. *Int. J. Environ. Res. Public Health*, 16(9), 2019, 1571.
31. Mester A, Apostu D, Ciobanu L, Piciu A, Lucaciu O, Campian RS, *et al* The impact of proton pump inhibitors on bone regeneration and implant osseointegration. *Drug Metab. Rev.,* 51(3), 2019, 330–339.
32. Ariel H, Cooke JP. Cardiovascular risk of proton pump inhibitors. *Methodist Debakey Cardiovasc. J.,* 15(3), 2019, 214.
33. Helgadottir H, Bjornsson ES. *et al* Problems associated with deprescribing of proton pump inhibitors. *Int. J. Mol. Sci.*, 20(21), 2019, 5469.
34. Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures. *Curr. Treat. Options Gastroenterol.,* 12(4), 2014, 414–423.
35. Freedberg DE, Haynes K, Denburg MR, Zemel BS, Leonard MB, Abrams JA, *et al* Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. *Osteoporos. Int.,* 26(10), 2015, 2501–2507.
36. Andersen BN, Johansen PB, Abrahamsen B. *et al* Proton pump inhibitors and osteoporosis. *Curr. Opin. Rheumatol*., 28(4), 2016, 420–425.
37. Oncken C, Prestwood K, Kleppinger A, Wang Y, Cooney J, Raisz L. *et al* Impact of smoking cessation on bone mineral density in postmenopausal women. *J. Womens Health,* 15(10), 2006, 1141–1150.
38. Sommer I, Erkkilä AT, Järvinen R, Mursu J, Sirola J, Jurvelin JS, e *et al* Alcohol consumption and bone mineral density in elderly women. *Public Health Nutr.,* 16(4), 2012, 704–712.
39. López-Larramona G, Lucendo AJ, González-Delgado L. *et al* Alcoholic liver disease and changes in bone mineral density. *Rev. Esp. Enferm. Dig.,* 105(10), 2013, 609–621.
40. Cho Y, Choi S, Kim K, Lee G, Park SM. *et al* Association between alcohol consumption and bone mineral density in elderly Korean men and women. *Arch. Osteoporos.,* 13, 2018, 46.

41. McVey MK, Geraghty AA, O'Brien EC, McKenna MJ, Kilbane MT, Crowley RK, *et al*. The impact of diet, body composition, and physical activity on child bone mineral density at five years of age—findings from the ROLO Kids Study. *Eur. J. Pediatr.,* 179(1), 2019, 121–131.

Cite this article:
Shaik Suhani, Fathima Juwairia, Nagalakshmi M, Shaik Reshma, Dr Lavanya A. Evidence-Based Management of Gastroesophageal Reflux Disease: Pathophysiology, Pharmacotherapy, And the Expanding Role of Pharmacists. *International Journal of Pharmaceutical Research & Analysis,* 2026;16(2):77-86.